<table id="table14" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 14: Clinically Important Drug Interactions: Effect of other Drugs on INTUNIV<sup>Â®</sup>
</caption>
<col align="left" valign="top" width="34%"></col>
<col align="left" valign="top" width="33%"></col>
<col align="left" valign="top" width="33%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Concomitant Drug Name or Drug Class</th>
<th stylecode="Rrule">Clinical Rationale and Magnitude of Drug Interaction</th>
<th stylecode="Rrule">Clinical Recommendation</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">CYP3A4 inhibitors, e.g.,ketoconazole</td>
<td stylecode="Rrule">Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a 200% increase in exposure</td>
<td stylecode="Rrule">Consider dose reduction <content stylecode="italics">[see <linkhtml href="#S2.7">Dosage and administration (2.7)</linkhtml>]</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">CYP3A4 inducers, e.g., rifampin</td>
<td stylecode="Rrule">Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a 60% decrease in exposure</td>
<td stylecode="Rrule">Consider dose increase <content stylecode="italics">[see <linkhtml href="#S2.7">Dosage and administration (2.7)</linkhtml>]</content>
</td>
</tr>
</tbody>
</table>